Wong, Hong Yuen
Sheng, Quanhu http://orcid.org/0000-0001-8951-9295
Hesterberg, Amanda B.
Croessmann, Sarah
Rios, Brenda L.
Giri, Khem
Jackson, Jorgen
Miranda, Adam X. http://orcid.org/0000-0002-3140-1953
Watkins, Evan
Schaffer, Kerry R.
Donahue, Meredith
Winkler, Elizabeth
Penson, David F.
Smith, Joseph A.
Herrell, S. Duke
Luckenbaugh, Amy N.
Barocas, Daniel A.
Kim, Young J. http://orcid.org/0000-0001-8434-4561
Graves, Diana
Giannico, Giovanna A. http://orcid.org/0000-0002-0326-3207
Rathmell, Jeffrey C. http://orcid.org/0000-0002-4106-3396
Park, Ben H.
Gordetsky, Jennifer B. http://orcid.org/0000-0002-0745-2160
Hurley, Paula J. http://orcid.org/0000-0003-1487-9282
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (T32CA009592, 2T32CA009582-32, R01CA217987)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA214494, R01CA211695-01A1, 5 R01 CA218526-04)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
American Cancer Society (131356-RSG-17-160-01-CSM)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 13 March 2022
Accepted: 3 October 2022
First Online: 13 October 2022
Competing interests
: P.J.H., B.H.P., Y.J.K., and J.R. declare the following potential competing interests. P.J.H. receives royalties from Horizon Discovery, LTD for the generation of targeted cell lines under a licensing agreement between Horizon Discovery, LTD and Johns Hopkins University. B.H.P. is a paid consultant for Jackson Labs, EQRx, Hologic, Sermonix, is a paid scientific advisory board member for Celcuity Inc., and receives research funding from GE Healthcare, Lilly, and Pfizer. Under separate licensing agreements between Horizon Discovery, LTD and The Johns Hopkins University, B.H.P. is entitled to a share of royalties received by the University on sales of products. The terms of this arrangement are being managed by Johns Hopkins University in accordance with its conflict-of-interest policies. Y.J.K. is a full-time stockholding employee of Regeneron with stock options. J.R. is a founder, scientific advisory board member, and stockholder of Sitryx Therapeutics, a scientific advisory board member and stockholder of Caribou Biosciences, a member of the scientific advisory board of Nirogy Therapeutics, has consulted for Merck, Pfizer, and Mitobridge within the past three years, and has received research support from Incyte Corp., Calithera Biosciences, and Tempest Therapeutics. The other authors declare no competing interests.